Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Pipeline of Drugs ... very light in Canada
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 11, 2022 3:29pm
99 Views
Post# 34305144

RE:RE:Pipeline of Drugs ... very light in Canada

RE:RE:Pipeline of Drugs ... very light in Canada
gudisgood wrote: Regarding Imvexxy and Bijuva, those will be launched in 2023. Lenvima and Halaven will be launched "early 2022". The Incyte drugs will be submitted in 2022, so launch likely in 2023.

I'd imagine that, for now, with many products/markets in a launch/growth phase, and with Exelon transferring over soon as well, we have our hands full with the current portfolio for the time being.

The goal is to get to get more products into the pipeline to be launched in 2023-2024. If there's a portfolio of drugs to buy that are already in the market, or some bolt-on acquisition to strengthen our platform, that's not too bad either.

By the way, nice to see the buybacks continued in December:
Jan 5/22 Dec 31/21 Knight Therapeutics Inc. Direct Ownership Common Shares 38 - Redemption, retraction, cancellation, repurchase -1,021,080  
Jan 5/22 Dec 29/21 Knight Therapeutics Inc. Direct Ownership Common Shares 38 - Redemption, retraction, cancellation, repurchase 32,415 $5.25
Jan 5/22 Dec 24/21 Knight Therapeutics Inc. Direct Ownership Common Shares 38 - Redemption, retraction, cancellation, repurchase 20,100 $5.24
Jan 5/22 Dec 23/21 Knight Therapeutics Inc. Direct Ownership Common Shares 38 - Redemption, retraction, cancellation, repurchase 44,715 $5.24
 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities